An internal standard for the quantification of cabergoline
Related Products
Unlabeled Version(s)
23934Cabergoline
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cabergoline-d6

Item No. 31690

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[3-((dimethyl-d3)amino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-ergoline-8β-carboxamide
CAS Number
2738376-76-4
Molecular Formula
C26H31D6N5O2
Formula Weight
457.6
Purity
≥99% deuterated forms (d1-d6)
Formulation
A solution in acetonitrile
Solubility(Learn about Variance in Solubility)
Acetonitrile: SolubleDMSO: Soluble
SMILES
O=C(NCC)N(CCCN(C([2H])([2H])[2H])C([2H])([2H])[2H])C([C@H]1CN(CC=C)[C@@]2([H])[C@](C3=C4C(C2)=CNC4=CC=C3)([H])C1)=O
InChi Code
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1/i3D3,4D3
InChi Key
KORNTPPJEAJQIU-QYFGKBEYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $189

    Add

    250 µg

    $442

    Add

    500 µg

    $836

    Add

    1 mg

    $1,579

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Cabergoline-d6 is intended for use as an internal standard for the quantification of cabergoline (Item No. 23934) by GC- or LC-MS. Cabergoline is a dopamine D2 receptor agonist (Ki = 0.912 nM in rat striatal homogenates).1 It is selective for dopamine D2 over D1 receptors (Ki = 6,935 nM). Cabergoline inhibits prolactin secretion in, and growth of, isolated rat pituitary tumor cells in a concentration-dependent manner, an effect that can be blocked by the dopamine D2 receptor antagonist haloperidol (Item No. 12014).2 Cabergoline reduces phosphorylation of mammalian target of rapamycin (mTOR) and induces the formation of LC3 puncta, a marker of autophagy, and apoptosis in MMQ rat pituitary cells.3 In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a cynomolgus monkey model of Parkinson's disease induced by MPTP.4 Formulations containing cabergoline have been used in the treatment of prolactinomas.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Miyagi, M., Itoh, F., Taya, F., et al. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol. Pharm. Bull. 19(9), 1210-1213 (1996).

    2. Eguchi, K., Kawamoto, K., Uozumi, T., et al. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: In vitro culture studies. Endocr. J. 42(3), 413-420 (1995).

    3. Lin, S.J., Leng, Z.G., Guo, Y.H., et al. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline. Oncotarget 6(36), 39329-39341 (2015).

    4. Grondin, R., Goulet, M.T., Di Paolo, T., et al. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res. 735(2), 298-306 (1996).